Skip to main content
PMC home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
. 2003 Oct;95(10):982–985.

Use of liposomal amphotericin B in the treatment of disseminated coccidioidomycosis.

Suresh Antony 1, Delfina C Dominguez 1, Elsa Sotelo 1
PMCID: PMC2594503  PMID: 14620712

Abstract

Disseminated fungal infection is an important cause of morbidity and mortality, especially in immunocompromised hosts. Amphotericin B is an important part of the therapy and treatment of invasive and life-threatening mycoses. We present a case of disseminated coccidioidomycosis in a patient who was successfully treated with liposomal amphotericin B (AmBisome) on steroid therapy. It appears that liposomal amphotericin B may offer an alternative and safe option in the treatment of coccidioidomycosis when conventional amphotericin B cannot be used.

Full text

PDF
982

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adler-Moore Jill, Proffitt Richard T. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother. 2002 Feb;49 (Suppl 1):21–30. doi: 10.1093/jac/49.suppl_1.21. [DOI] [PubMed] [Google Scholar]
  2. Boswell G. W., Buell D., Bekersky I. AmBisome (liposomal amphotericin B): a comparative review. J Clin Pharmacol. 1998 Jul;38(7):583–592. doi: 10.1002/j.1552-4604.1998.tb04464.x. [DOI] [PubMed] [Google Scholar]
  3. Dismukes W. E. Introduction to antifungal drugs. Clin Infect Dis. 2000 Apr 20;30(4):653–657. doi: 10.1086/313748. [DOI] [PubMed] [Google Scholar]
  4. Dupont Bertrand. Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother. 2002 Feb;49 (Suppl 1):31–36. doi: 10.1093/jac/49.suppl_1.31. [DOI] [PubMed] [Google Scholar]
  5. Galgiani J. N., Catanzaro A., Cloud G. A., Johnson R. H., Williams P. L., Mirels L. F., Nassar F., Lutz J. E., Stevens D. A., Sharkey P. K. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group. Ann Intern Med. 2000 Nov 7;133(9):676–686. doi: 10.7326/0003-4819-133-9-200011070-00009. [DOI] [PubMed] [Google Scholar]
  6. Galgiani J. N. Coccidioidomycosis: a regional disease of national importance. Rethinking approaches for control. Ann Intern Med. 1999 Feb 16;130(4 Pt 1):293–300. doi: 10.7326/0003-4819-130-4-199902160-00015. [DOI] [PubMed] [Google Scholar]
  7. Hay R. J. Liposomal amphotericin B, AmBisome. J Infect. 1994 May;28 (Suppl 1):35–43. doi: 10.1016/s0163-4453(94)95956-0. [DOI] [PubMed] [Google Scholar]
  8. Kontoyiannis D. P., Andersson B. S., Lewis R. E., Raad I. I. Progressive disseminated aspergillosis in a bone marrow transplant recipient: response with a high-dose lipid formulation of amphotericin B. Clin Infect Dis. 2001 Feb 23;32(5):E94–E96. doi: 10.1086/319208. [DOI] [PubMed] [Google Scholar]
  9. Leenders A. C., Reiss P., Portegies P., Clezy K., Hop W. C., Hoy J., Borleffs J. C., Allworth T., Kauffmann R. H., Jones P. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS. 1997 Oct;11(12):1463–1471. doi: 10.1097/00002030-199712000-00010. [DOI] [PubMed] [Google Scholar]
  10. Olivere J. W., Meier P. A., Fraser S. L., Morrison W. B., Parsons T. W., Drehner D. M. Coccidioidomycosis--the airborne assault continues: an unusual presentation with a review of the history, epidemiology, and military relevance. Aviat Space Environ Med. 1999 Aug;70(8):790–796. [PubMed] [Google Scholar]
  11. Ringdén O., Meunier F., Tollemar J., Ricci P., Tura S., Kuse E., Viviani M. A., Gorin N. C., Klastersky J., Fenaux P. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother. 1991 Oct;28 (Suppl B):73–82. doi: 10.1093/jac/28.suppl_b.73. [DOI] [PubMed] [Google Scholar]
  12. Tiphine M., Letscher-Bru V., Herbrecht R. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability. Transpl Infect Dis. 1999 Dec;1(4):273–283. doi: 10.1034/j.1399-3062.1999.010406.x. [DOI] [PubMed] [Google Scholar]
  13. Walsh T. J., Finberg R. W., Arndt C., Hiemenz J., Schwartz C., Bodensteiner D., Pappas P., Seibel N., Greenberg R. N., Dummer S. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med. 1999 Mar 11;340(10):764–771. doi: 10.1056/NEJM199903113401004. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES